GAO Yi, LI Weixing, WANG Zhonggeng, et al
Journal of Clinical Radiology.
2025, 44(10):
1975-1981.
Objective To explore the value of 18F-FDG PET/CT imaging parameters combined with serum miR-345 and miR-20a in predicting the efficacy and prognosis of immune therapy in advanced non-small cell lung cancer (NSCLC). Methods A total of 158 advanced NSCLC patients who received immune therapy at our hospital from January 2021 to June 2024 were included in the study. All patients underwent 18F-FDG-PET/CT imaging and serum miR-345 and miR-20a level detection before receiving immune therapy. The imaging parameters of 18F-FDG-PET/CT included maximum standard uptake value (SUVmax),tumor metabolic volume (MTV),and total lesion glycolysis (TLG). Clinical and pathological data were collected,and treatment efficacy was evaluated using the RECIST 1.1 criteria. All patients were followed up for 10-24 months through telephone,outpatient,and inpatient visits to collect tumor assessment results,disease progression,and overall survival. The efficacy of the immune therapy was assessed using Kaplan-Meier survival curves for progression-free survival (PFS) and overall survival (OS). Spearman correlation analysis was conducted to assess the correlation between clinical efficacy and 18F-FDG-PET/CT imaging parameters and serum miR-345 and miR-20a levels. The effectiveness of using 18F-FDG-PET/CT imaging parameters and serum miR-345 and miR-20a levels to predict clinical efficacy was analyzed using receiver operating characteristic (ROC) curves. Univariate and multivariate Cox analysis were used to identify risk factors influencing patient prognosis. Results The average values for SUVmax,MTV,and TLG were (12.52 ± 5.26),(97.36 ± 13.63) cm³,and (1669.74 ± 705.46),respectively. The relative expression levels of miR-345 and miR-20a were (24.54 ± 2.11) and (25.38 ± 2.33),respectively. The objective response rate (ORR) of immune therapy in 158 patients was 44.30% (70/158),and the disease control rate (DCR) was 89.87% (142/158). Compared to the non-responding group,the SUVmax,MTV,and TLG values,as well as miR-345 levels,decreased in the responding group,while serum miR-20a levels increased,with statistically significant differences (P < 0.05). Spearman correlation analysis showed that immune therapy efficacy was negatively correlated with SUVmax,MTV,TLG,and miR-345 levels,while it was positively correlated with miR-20a levels. ROC analysis indicated that SUVmax,MTV,TLG,miR-345 2-∆∆Ct,and miR-20a 2-∆∆Ct had good predictive ability for NSCLC immune therapy efficacy,with combined treatment showing higher sensitivity and specificity. During the follow-up period,80 patients died,with a mortality rate of 50.63% (80/158). Kaplan-Meier survival curve analysis showed that the median PFS and mOS of all patients were 6.75 months (95% CI 6.20-8.15) and 20.81 months (95% CI 19.34-20.06),respectively. Cox multivariate analysis revealed that ECOG performance status,degree of differentiation,tumor size,distant metastasis,clinical stage,SUVmax,MTV,TLG,miR-345,and miR-20a were independent risk factors affecting the prognosis of NSCLC patients undergoing immune therapy. Conclusion 18F-FDG-PET/CT imaging parameters (SUVmax,MTV,TLG) combined with serum miR-345 and miR-20a levels can effectively predict the efficacy and prognosis of immune therapy in advanced non-small cell lung cancer patients.